PMID- 32012714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Jan 27
TI  - Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: 
      Ready 'N Able to Improve Clinical Outcome?
LID - 10.3390/cancers12020299 [doi]
LID - 299
AB  - Targeting and exploiting the immune system has become a valid alternative to 
      conventional options for treating cancer and infectious disease. Dendritic cells 
      (DCs) take a central place given their role as key orchestrators of immunity. 
      Therapeutic vaccination with autologous DCs aims to stimulate the patient's own 
      immune system to specifically target his/her disease and has proven to be an 
      effective form of immunotherapy with very little toxicity. A great amount of 
      research in this field has concentrated on engineering these DCs through 
      ribonucleic acid (RNA) to improve vaccine efficacy and thereby the historically 
      low response rates. We reviewed in depth the 52 clinical trials that have been 
      published on RNA-engineered DC vaccination, spanning from 2001 to date and 
      reporting on 696 different vaccinated patients. While ambiguity prevents reliable 
      quantification of effects, these trials do provide evidence that RNA-modified DC 
      vaccination can induce objective clinical responses and survival benefit in 
      cancer patients through stimulation of anti-cancer immunity, without significant 
      toxicity. Succinct background knowledge of RNA engineering strategies and concise 
      conclusions from available clinical and recent preclinical evidence will help 
      guide future research in the larger domain of DC immunotherapy.
FAU - Willemen, Yannick
AU  - Willemen Y
AD  - Laboratory of Experimental Hematology, VAXINFECTIO, Faculty of Medicine and 
      Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
FAU - Versteven, Maarten
AU  - Versteven M
AD  - Laboratory of Experimental Hematology, VAXINFECTIO, Faculty of Medicine and 
      Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
FAU - Peeters, Marc
AU  - Peeters M
AD  - Center for Oncological Research, Faculty of Medicine and Health Sciences, 
      University of Antwerp, 2610 Antwerp, Belgium.
FAU - Berneman, Zwi N
AU  - Berneman ZN
AD  - Laboratory of Experimental Hematology, VAXINFECTIO, Faculty of Medicine and 
      Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
FAU - Smits, Evelien L J
AU  - Smits ELJ
AD  - Laboratory of Experimental Hematology, VAXINFECTIO, Faculty of Medicine and 
      Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
AD  - Center for Oncological Research, Faculty of Medicine and Health Sciences, 
      University of Antwerp, 2610 Antwerp, Belgium.
LA  - eng
GR  - not specified/Kom op tegen Kanker/
GR  - 2014-155/Stichting Tegen Kanker/
GR  - 111038/Agentschap voor Innovatie door Wetenschap en Technologie/
PT  - Journal Article
PT  - Review
DEP - 20200127
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7072269
OTO - NOTNLM
OT  - cancer
OT  - dendritic cell
OT  - human immunodeficiency virus
OT  - immunotherapy
OT  - ribonucleic acid
OT  - vaccination
COIS- The authors declare no conflict of interest. The funders had no role in the 
      collection, analyses, or interpretation of data; in the writing of the 
      manuscript, or in the decision to publish the results.
EDAT- 2020/02/06 06:00
MHDA- 2020/02/06 06:01
PMCR- 2020/01/27
CRDT- 2020/02/05 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/01/06 00:00 [revised]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/02/05 06:00 [entrez]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/02/06 06:01 [medline]
PHST- 2020/01/27 00:00 [pmc-release]
AID - cancers12020299 [pii]
AID - cancers-12-00299 [pii]
AID - 10.3390/cancers12020299 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Jan 27;12(2):299. doi: 10.3390/cancers12020299.